

REGENERATIVE MEDICINE MARKETS *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers



TABLE OF CONTENTS

1.	Overview	17
1.1	Statement of Report	17
1.2	Scope of this Report	19
1.3	Methodology	19
1.4	Executive Summary	20
2.	Regenerative Medicine: An Overview of Segments	22
2.1	Tissue Engineering	22
2.1.1	Tissue-Engineered Skin	23
2.1.2	Tissue-Engineered Cartilage	23
2.1.3	Tissue-Engineered Bone	23
2.1.4	Tissue-Engineered Peripheral Nerves	24
2.1.5	Tissue-Engineered Cornea	24
2.1.6	Tissue-Engineered Blood Vessels	24
2.2	An Overview of Tissue Engineering and Regenerative Medicine (TERM)	25
2.2.1	Tissue-Engineered Products and Their Applications	26
2.2.1.1	Skin, Cartilage, Bone and Urological Applications	26
2.2.1.2	Cardiovascular Applications	27
2.2.1.3	Neurological Applications	27
2.2.1.4	Pancreas, Liver and Kidney Applications	28
2.2.1.5	Ophthalmic Applications	28
2.2.1.6	Dental Applications	28
2.2.1.7	Autologous and Allogeneic Products	28
2.2.2	Geographic Distribution of TERM Firms in the Five Focus Countries	29
2.3	Cell Therapy	32
2.3.1	Number of Patients Treated between 1988 and 2010 by Regenerative Medicine Therapies	34
2.3.2	Cell Culture Products	34
2.3.2.1	In Vitro Test Kits	36
2.3.2.2	Suppliers of Cells and Tissues	37
2.3.2.3	Suppliers of Culture Media and Reagents	38
2.3.2.4	Equipments for Stem Cell Research	38
2.3.2.5	Computer Software for Stem Cell Research	39
2.3.3	Overall Picture of Cell Therapy Industry	41
2.3.3.1	The Size of Cell Therapy Industry	41
2.3.3.2	The Age, Size and Location of Firms	42
2.3.3.3	Technology and Disease Focus	44
2.3.4	Cell Therapy Products and Companies	44
2.3.4.1	First Generation (Non-Stem Cell-based) Primary Products	46
2.3.4.2	Second Generation (Stem Cell-Based) Primary Products	47
2.3.4.3	Secondary Products	47
2.3.4.4	Products in Development	48
2.3.5	The Disease Focus of Clinical Trials	49
2.3.5.1	Stem Cell Industry Pipeline	50
2.3.6	Industry Collaboration in Stem Cell Space	52
2.3.6.1	Commercial Success in Stem Cell Industry	53
2.3.6.2	Major Shift to Stem Cells from Non-Stem Cell Technologies	53
2.3.6.3	Challenges to Commercial Development of Cell Therapies	54
2.3.6.4	Partnership of Stem Cell Companies with Large Pharmaceutical Companies	55
2.3.6.5	Strategic Approaches for Cell-Based Companies	56
2.3.6.6	The Need for Support from Large Pharmaceuticals	57
2.4	Scaffolding Biomaterials	58
2.4.1	Biomaterial Scaffolds in Regenerative Medicine	59
2.5	Growth Factors	60

3.	Regenerative Medicine: The Next Evolution of Medical Treatments	62
3.1	Scope of this Chapter	62
3.2	Need for Regenerative Medicine	62
3.3	Current State of Regenerative Medicine	62
3.4	Future of Regenerative Medicine	63
3.5	Number of Products in Pipeline	63
3.6	Projected Timeline for Regenerative Medicine	67
3.7	Regenerative Medicine Products in the Market	68
3.7.1	Medtronic's Infuse Bone Graft and the LT-Cage Device	69
3.7.2	Genzyme's Carticel	69
3.7.3	Stryker's OP-1	70
3.7.4	Osyris/Nuvasive's Osteocele [®]	71
3.7.5	RTI's Spinal Implants	71
3.7.6	Organogenesis' Apligraf [®]	72
3.7.7	Advanced BioHealing's Dermagraft [®]	72
3.7.8	Integra's Bilayer Matrix Wound Dressing	73
3.7.9	LifeCell's Alloderm [®]	73
3.7.10	Cytori Therapeutics' Celution [®]	74
3.8	Other Products of Importance in Regenerative Medicine	74
3.8.1	Tissue-Engineered Wound Healing Products	74
3.8.1.1	Oasis [®]	75
3.8.1.2	Permacol [™]	76
3.8.1.3	EZ-Derm [®]	76
3.8.1.4	Matriderm [®]	76
3.8.1.5	TransCyte [®]	77
3.8.1.6	ICX-SKN [®]	77
3.8.1.7	OrCel [®]	78
3.8.1.8	Epicel [®]	78
3.8.1.9	Myskin [™]	78
3.8.1.10	VCT01 [™]	79
3.8.2	ICX-TRC—Hair Regeneration Therapy	79
3.8.3	Cartilage Regeneration	79
3.8.3.1	Novocart [™]	79
3.8.3.2	BioSeed [®] -C	80
3.8.3.3	BioSeed [®] -Oral Bone	80
3.8.3.4	Chondrotissue [®]	80
3.8.3.5	co.don Chondrotransplant [®]	80
3.8.3.6	co.don Chondrotransplant [®] DISC	80
3.8.3.7	co.don Chondrosphere [®]	80
3.8.3.8	co.don Osteotransplant [®] DENT	80
3.8.3.9	MACI [®] Implant	81
3.8.3.10	Cartilink-3 [®]	81
3.8.3.11	Accell Evo3 [®] Demineralized Bone Matrix	81
3.8.3.12	OsSatura BCP [™]	81
3.8.4	Mozobil	81
4.	Market Analysis of Regenerative Medicine Sector	82
4.1	Scope of this Chapter	82
4.1.1	Market for Regenerative Medicine Products	82
4.1.2	The Different Characteristics of Regenerative Medicine Industry in the Recent Past	85
4.1.3	Potential Market for Regenerative Medicine in the U.S.	86
4.2	Global Market for Stem Cells	87
4.3	Market for Cell Therapy in the U.S.	88
4.4	Global Market for Cord Blood Stem Cells	88
4.4.1	Public Cord Blood Banks	89
4.4.2	Private Cord Blood Banks	90

5.	Business Models and Requirements for a Successful Regenerative Medicine Industry	91
5.1	Scope of this Chapter	91
5.1.1	The Limited Success Achieved by the Regenerative Medicine Products	91
5.1.2	Business Models in Regenerative Medicine	91
5.1.3	Current Model for Autologous Cell Therapies	93
5.1.4	Current Models for Allogeneic Cell Therapies	94
5.1.5	Key Factors for Successful Business Models for Cell Therapies	95
5.2	Commercial Manufacturing of Cell Therapy Products: Requirements	96
5.2.1	Elements of Commercial Manufacturing	96
5.2.1.1	Regulatory Requirements	96
5.2.1.2	Manufacturing Process Scale	96
5.2.1.3	In-House Manufacturing	97
5.2.1.4	Contract Manufacturing: Commercial and Academic	97
6.	Diseases with Potential Applications for Regenerative Medicine	100
6.1	Regenerative Medicine and Diabetes	102
6.2	Regenerative Medicine for Cardiac Repair	103
6.3	Regenerative Medicine in Orthopedics	103
6.3.1	Orthobiologics in Orthopedics	103
6.3.2	Growth Factor Therapies in Orthopedics	104
6.3.3	Stem Cell Therapies in Orthopedics	104
6.4	Regenerative Medicine in Liver Diseases	104
6.4.1	Hepatocyte-Like Cells for Liver Disease	105
6.4.2	Cell Therapy for Liver Cirrhosis	105
6.4.3	CD 34+ Cells	105
6.5	Regenerative Medicine in Retinal Replacement Therapy	105
6.5.1	Retinal Transplantation	106
6.6	Regenerative Medicine in Central Nervous System (CNS) Disorders	106
6.6.1	Clinical Activity for Stem Cell Transplantation into the CNS	106
7.	Current Stem Cell Research and Federal Funding in the U.S.	107
7.1	Scope of this Chapter	107
7.2	Stem Cell Policies in North America	107
7.3	Stem Cell Policies in South America	108
7.4	Stem Cell Policies in Europe	108
7.5	Stem Cell Policies in Asia/Oceania	110
7.6	Stem Cell Policies in Africa	111
7.7	Stem Cell Research and California Institute for Regenerative Medicine (CIRM)	111
7.7.1	CIRM Collaborative Funding	112
7.7.2	CIRM's funding for Clinical Applications	113
7.7.3	Early Translational Awards	113
7.7.4	CIRM's Disease Team Awards	114
7.8	Stem Cell Research Programs in Connecticut Department of Public Health	114
7.8.1	Seed Grant Awards from Connecticut Stem Cell Research Program in 2010	114
7.8.2	Established Investigator Awards from Connecticut Stem Cell Research Program in 2010	114
7.8.3	Group Project Awards from Connecticut Stem Cell Research Program in 2010	116
7.8.4	Core Facility Awards from Connecticut Stem Cell Research Program in 2010	116
7.8.5	Maryland Technology Development Corporation (TEDCO)	116
7.8.6	TEDCO's Fort Detrick Technology Transfer Initiative (FDTTI)	116
7.8.7	Johnson & Johnson Investment Fund	116
7.8.8	TEDCO's NAVAIR Technology Insertion (NAVTI) Program	116
7.8.9	TEDCO's TechStart Program	116
7.8.10	TEDCO's University Technology Development Fund (UTDF)	116
7.8.11	TEDCO's Working Capital Loan Fund	116
7.8.12	Maryland Technology Transfer and Commercialization Fund (MTTCF)	117

7.8.13	Maryland Stem Cell Research Fund	117
7.9	The New Jersey Commission on Science and Technology (NJCST)	117
7.9.1	Investigator Initiated Research Projects (IIRP) and Innovative, Developmental or Exploratory Activities (IDEA) in Stem Cell Research	118
7.9.2	Targeted Request for Applications for Investigation of iPS and Other Derivation Approaches	119
7.9.3	Shared Facilities/Resources and Equipment/Instrumentation for Stem Cell Research	119
7.9.4	Consortia Planning Awards	119
7.9.5	Institutional Development	120
7.10	Center for Stem Cell and Regenerative Medicine	120
7.11	Global Funding for Regenerative Medicine	120
7.12	Federal Funding of Stem Cell Research in the U.S.: Past and Present	120
7.12.1	The U.S. National Institute of Health (NIH) Guidelines to hESC Research	121
7.12.2	Types of Research Ineligible for NIH Funding	121
7.12.3	NIH's Leadership in Providing Funds for Stem Cell Research	121
7.12.4	NIH Guidelines Addressing the Projected Growth of Stem Cell-related Clinical Trials	121
7.12.5	Federal Agencies Providing Funds for Stem Cell Research	122
8.	Company Profiles	123
8.1	Aastrom Biosciences, Inc.	123
8.1.1	Aastrom's Clinical Trial Programs	123
8.1.1.1	Dilated Cardiomyopathy	123
8.1.1.2	Critical Limb Ischemia	123
8.1.1.3	Osteonecrosis of the Femoral Head	123
8.1.1.4	Other Bone Disorders	123
8.1.2	Product Development	124
8.1.3	Aastrom's Cell Manufacturing	124
8.1.4	Aastrom's Business Performance	124
8.2	Advanced Cell Technology, Inc. (ACT)	125
8.2.1	ACT's Cellular Reprogramming	125
8.2.2	ACT's Stem Cell Differentiation	126
8.2.2.1	ACT's Retinal Pigment Epithelium (RPE) Program	126
8.2.2.2	ACT's Hemangioblast Program	126
8.2.2.3	ACT's Adult Stem Cell Program	126
8.2.3	ACT's Intellectual Property	126
8.2.4	ACT's Business Performance	128
8.2.5	ACT's Investment in Research and Development	128
8.3	Aldagen, Inc.	129
8.3.1	Aldagen's ALD-201	129
8.3.2	Aldagen's ALD-301	129
8.4	Altrika Ltd.	129
8.4.1	Myskin™	129
8.4.2	Cryoskin™	130
8.4.3	Altrika's Future Products	130
8.4.3.1	Lyphoderm	130
8.4.3.2	Corneal Bandage	130
8.4.3.3	Leukodepletion Filters	131
8.5	Alseres Pharmaceuticals, Inc.	131
8.5.1	Alseres' Product Pipeline	131
8.5.1.1	Celthrin®—A Rho Inhibitor	132
8.5.1.2	Inosine	132
8.5.1.3	Oncomodulin and ALSE-100	133
8.5.1.4	Altropane®—PD	133
8.5.2	Alseres' Science and Technology	134
8.5.2.1	Nerve Repair Pathways	134
8.5.2.2	The Pro-Regenerative Pathway	135
8.5.2.3	The Anti-Regenerative Pathway	135

8.5.2.4	Molecular Imaging	136
8.5.2.5	Dopamine Transporter	136
8.6	Amgen, Inc.	137
8.6.1	Amgen's Marketed Products	139
8.6.1.1	Aranesp® (Darbepoetin Alfa)	139
8.6.1.2	Epogen® (Epoetin Alfa)	139
8.6.1.3	Neulasta® (Pegfilgrastim)/Neupogen® (Filgrastim)	140
8.6.1.4	Enbrel® (Etanercept)	141
8.6.1.5	Sensipar® (Cinacalcet)	141
8.6.1.6	Vectibix® (Panitumumab)	142
8.6.1.7	Nplate® (Romiplostim)	143
8.6.2	Amgen's Marketing and Distribution	143
8.6.3	Amgen's Overall Business Performance	144
8.7	Amorcyte, Inc.	145
8.7.1	Amorcyte's Technology	145
8.7.1.1	AMR-001	145
8.8	AnGes MG, Inc.	146
8.8.1	AnGes' Genetic Medicine	146
8.8.2	HGF Genetic Medicine	147
8.8.3	Hemagglutinating Virus of Japan (HVJ) Envelope Vector	147
8.8.4	NF-kB Decoy Oligodeoxynucleotide	148
8.9	Angioblast Systems, Inc.	149
8.9.1	Angioblast's Technology and Applications	149
8.9.1.1	Allogenic Adult Stem Cells	149
8.9.1.2	Protein Therapeutics	150
8.9.1.3	Gene Slicing	150
8.10	Angion Biomedica, Corp.	150
8.10.1	HGF and c-Met Signaling in Tissue Repair and Organ Regeneration	151
8.10.2	PARP-1	152
8.10.3	TGFβ1	152
8.11	Ars Arthro Biotechnology, Inc.	153
8.11.1	CaReS®	153
8.11.2	Fibrocell	153
8.11.3	Fibroplus	153
8.12	Arteriocyte Medical Systems, Inc.	154
8.12.1	Blood Pharming	154
8.12.2	Cardiac Ischemia	154
8.12.3	Critical Limb Ischemia	154
8.12.4	Malaria Research	155
8.12.5	Orthopedic Regenerative Medicine	155
8.12.6	Proliferative Diabetic Retinopathy	155
8.12.7	Wound Healing	155
8.13	Athersys, Inc.	156
8.13.1	Athersys' Pipeline	156
8.13.2	MultiStem for Stem Cell Therapy	156
8.13.3	MultiStem for Bone Marrow (BM) Transport Support	157
8.13.4	MultiStem for Acute Myocardial Infarction	157
8.13.5	MultiStem for Stroke	157
8.13.6	Treatments for Obesity	158
8.13.7	Histamine H3 Receptor Antagonists	158
8.13.8	Athersys' Collaborations and Partnerships	158
8.13.8.1	Collaboration with Pfizer	158
8.13.8.2	Collaboration with Angiotech	158
8.13.8.3	Collaboration with Bristol-Myers Squibb	158
8.13.9	Athersys' Research and Development	158
8.13.10	Athersys' Business Performance	159

8.14	BeFutur Biotechnologies	160
8.14.1	BeFutur's Technologies	160
8.14.1.1	Cells and Tissue Engineering	160
8.14.1.2	Serum-Free Technology	160
8.15	BioE, Inc.	160
8.15.1	BioE's Products	160
8.16	Bioheart, Inc.	161
8.16.1	Bioheart's Product Candidates	161
8.16.1.1	MyoCell®	161
8.16.1.2	MyoCell SDF-1	161
8.16.1.3	TGI 1200 Cell Isolation System	161
8.16.1.4	Bioheart 3370®	162
8.16.2	Bioheart's Patents and Proprietary Rights	162
8.17	BioLine Rx	162
8.17.1	BioLine's Product Pipeline	163
8.17.1.1	BL-1020 Schizophrenia	163
8.17.1.2	BL-1040 for Acute Myocardial Infarction	163
8.17.1.3	BL-5010 for Skin Lesions	163
8.17.1.4	BL-1021 for Neuropathic Pain	163
8.17.1.5	BL-2030 for Inflammation	163
8.17.1.6	BL-1023 for Parkinson's Disease	163
8.17.1.7	BL-4010 for Cancer	164
8.17.1.8	BL-4040 for Acute Kidney Failure	164
8.17.1.9	BL-5030 for Thromboembolic Diseases	164
8.17.1.10	BL-5040 for Cachexia and Inflammatory Bowel Disease	164
8.18	BIOMET	165
8.18.1	BIOMET 3i	165
8.18.2	Clotalyst® Autologous Serum Collection System	165
8.18.3	BioCUE™ Platelet Concentration System	165
8.19	BioMimetic Therapeutics, Inc.	165
8.19.1	BioMimetic's Product Candidates	165
8.19.2	BioMimetic's Research and Development	167
8.20	BioSafe Group SA	167
8.20.1	Sepax	167
8.20.2	Sepax System in Adult Stem Cell Banking	168
8.20.3	Coolmix	168
8.20.4	SepaxNet	168
8.21	BioTime, Inc.	169
8.21.1	BioTime's Stem Cell Products for Regenerative Medicine	169
8.21.2	BioTime's Embryome Database	169
8.21.3	BioTime's Progenitor and hES Cell Lines	170
8.21.4	BioTime's hES Cells Carrying Genetic Diseases	170
8.21.5	BioTime's ESspan™ Cell Growth Media	170
8.21.6	BioTime's ESpy™ Cell Lines	170
8.21.7	BioTime's Licensed Stem Cell Technology and Stem Cell Product Development Agreements	170
8.21.7.1	Wisconsin Alumni Research Foundation	170
8.21.7.2	ACTCellerate™ Technology	170
8.21.7.3	The iPS Technology	171
8.21.7.4	Lifeline	171
8.21.7.5	BioTime's Stem Cell Agreement with Reproductive Genetics Institute	171
8.21.8	BioTime's Plasma Volume Expanders and Related Products	171
8.21.8.1	Hextend	171
8.21.8.2	PentaLyte	171
8.22	Biovest International, Inc.	171
8.22.1	BiovaxID Cancer Vaccine	172
8.23	BrainStorm Cell Therapeutics, Inc.	172

8.23.1	BrainStorm's Technology	172
8.23.2	BrainStorm's Stem Cell Therapy	173
8.23.3	BrainStorm Technology—NurOwn™	173
8.24	Cardio3 BioSciences	174
8.24.1	Cardio3's Product Pipeline	174
8.24.1.1	C-Cure®	174
8.24.1.2	C-Cure2	174
8.24.1.3	Allo-Cure	175
8.24.1.4	G-Cure	175
8.24.1.5	C-Cath	175
8.24.2	Cardio3's Investors	175
8.25	CardioPolymers, Inc.	175
8.25.1	CardioPolymer's Products	176
8.25.1.1	Algisyl-LVR™	176
8.25.1.2	Plexisyl-AF™	176
8.25.2	CardioPolymer's Investors	176
8.26	CaridianBCT	177
8.26.1	Trima Accel® Automated Blood Collection System	177
8.26.2	Spectra Optia® Apheresis System	177
8.26.3	COBE® Spectra Apheresis System	177
8.26.4	Elutra® Cell Separation System	178
8.26.5	Atreus® Whole Blood Processing System	178
8.26.6	OrbiSac® System	178
8.26.7	COBE® 2991 Cell Processor	179
8.27	Cardium Therapeutics, Inc.	179
8.27.1	Cardium Biologics	180
8.27.2	Cardium's Tissue Repair Company	180
8.27.3	Cardium's Gene Activated Matrix™ (GAM) Technology	180
8.27.4	Cardium's Biologics and Stem Cells for Regenerative Medicine	180
8.28	Cellartis AB	180
8.28.1	Cellartis' Products	181
8.28.1.1	The hES-CMCT™ 2D: Cardiomyocyte Monolayers	181
8.28.1.2	The hES-CMCT™ 002: Cardiomyocyte Clusters	181
8.28.1.3	The hES-HEOT™ 002: Hepatocyte-like Cells	182
8.28.1.4	The hES-MPT™ 002.5: Mesenchymal Progenitors	182
8.28.1.5	The hES Cell Lines	183
8.28.1.6	SCED™ 461: Human ES Cells	183
8.28.1.7	Monoclonal Antibodies	183
8.28.2	Cellartis' Licensing Activities	184
8.29	Cellerix	184
8.29.1	Ontaril®	184
8.29.2	Cx501	185
8.30	Celgene Corporation	185
8.30.1	Celgene's Business Performance	186
8.30.2	Celgene's Commercial Stage Products	186
8.30.2.1	Revlimid® (Lenalidomide)	186
8.30.2.2	Thalomid® (Thalidomide)	187
8.30.2.3	Vidaza® (Azacitidine for Injection)	187
8.30.2.4	Ritalin® Family of Drugs	187
8.30.2.5	Alkeran® (Melphalan)	187
8.30.2.6	IMiDs® Compounds	187
8.30.2.7	Oral Anti-Inflammatory Agents	188
8.30.2.8	Kinase Inhibitors	188
8.30.2.9	Cellular Therapies	188
8.31	CellSeed, Inc.	189
8.31.1	CellSeed's Epithelial Cell Sheet for Corneal Regeneration	189

8.31.2	CellSeed's Regenerated Cardiac Patch	189
8.31.3	CellSeed's Epithelial Cell Sheet for Esophageal Regeneration	189
8.31.4	CellSeed's Cell Sheet for Periodontal Tissue Regeneration	189
8.31.5	CellSeed's Regenerated Cartilage Sheet	190
8.32	Cellular Dynamics International	190
8.32.1	The iCell Cardiomyocytes	190
8.32.2	Cellular Dynamics' Technology	190
8.33	Celltrix	191
8.33.1	Credurance	191
8.34	Cerco Medical	191
8.34.1	Cerco Medical's Concept	192
8.34.2	Bio-Artificial Endocrine Pancreas	192
8.35	Cook Biotech, Inc.	192
8.35.1	Cook's Technology	193
8.35.2	Biodesign™ Dural Graft	193
8.35.3	Dynamatrix™ Oral Graft	193
8.35.4	SiS Ophthalmic	193
8.35.5	Oasis® Wound Matrix	194
8.35.6	Biodesign™ Staple Line Reinforcement	194
8.35.7	Biodesign™ Hiatal Hernia Graft	194
8.35.8	ECM for Pericardial Closure	194
8.35.9	ECM for Cardiac Tissue Repair	194
8.35.10	Biodesign™ 8-Layer Tissue Graft	195
8.35.11	Biodesign™ Abdominal Lock Graft	195
8.35.12	Biodesign™ Hernia Graft	195
8.35.13	Biodesign™ Inguinal Hernia Graft	195
8.35.14	Biodesign™ Umbilical Hernia Graft	196
8.35.15	Biodesign™ Anterior Pelvic Floor Graft	196
8.35.16	Biodesign™ Fistula Plug	196
8.35.17	Biodesign™ Posterior Pelvic Floor Graft	197
8.35.18	Surgisis Biodesign® Peyronie's Repair Graft	197
8.35.19	Biodesign™ Tension-Free Urethral Sling	197
8.35.20	Biodesign™ Vaginal Erosion Repair Graft	198
8.35.21	AxoGuard™ Nerve Protector	198
8.35.22	AxoGuard™ Nerve Connector	198
8.35.23	FISH™ Femoral Introducer Sheath and Hemostasis Device	198
8.36	Cord Blood America (CBAI), Inc.	198
8.37	Cryo-Cell International, Inc.	198
8.37.1	Cryo-Cell's License Agreements	199
8.37.1.1	Cryo-Cell De Mexico	199
8.37.1.2	Asia Cryo-Cell Private Limited	199
8.37.1.3	Venezuela	199
8.37.1.4	China	199
8.37.1.5	Germany	200
8.37.1.6	Nicaragua	200
8.37.1.7	Pakistan	200
8.37.2	Uses of Cord Blood Stem Cells	200
8.38	Curis, Inc.	202
8.38.1	Curis' Business Performance	203
8.38.2	Curis' Research and Development	204
8.39	Cytori Therapeutics, Inc.	204
8.39.1	Cytori's Cosmetic and Reconstructive Surgery Market	206
8.39.2	Cytori StenSource® Cell Banking Market	206
8.40	Develogen AG	206
8.40.1	Develogen's Pipeline	207
8.40.1.1	DG3173—Somatostatin Analog	207

8.40.1.2	Insulin Sensitizers	207	
8.40.1.3	Beta Cell Regeneration Factor	207	
8.41	Effector Cell Institute, Inc (ECI)	207	
8.41.1	ECI's Cell-based Drug Discovery (CDD)	207	
8.41.2	ECI's Regenerative Medicine	208	
8.41.3	ECI's Cancer Therapeutic Agent Development Project (EC1301)	208	
8.41.4	ECI's Anti-Inflammatory Drug Development Project (FROUNT)	208	
8.41.5	ECI's High Throughput Screening by Automatic TAXIScan™ System	209	
8.41.6	ECI's Products	209	
8.41.6.1	TAXIScan™ System	209	
8.41.6.2	Cytorecon™	209	
8.41.6.3	TAXIScan-FL™	210	
8.42	Epistem plc	210	
8.42.1	Epistem's Cotract Research Services in Oncology	210	
8.42.2	Epistem's Xenografting Models	210	
8.42.3	Epistem's Cancer Cell Assays	211	
8.42.4	Epistem's Angiogenesis Models	211	
8.42.5	Epistem's Colon Cancer Models (Min/+)	211	
8.42.6	Epistem's Histology, IHC, ISH and Gene Expression Profiling	212	
8.42.7	Epistem's In Vitro Cytotoxicity Testing	212	
8.42.8	Epistem's Plucked Hair Immunohistochemistry	212	
8.42.9	Epistem's Emerging Protein Therapeutics	212	
8.42.10	Epistem's Biomarker Technology	213	
8.43	FivePrime Therapeutics, Inc.	213	
8.43.1	FivePrime's Technology	213	
8.43.2	FivePrime's Collaborations	215	
8.44	Forticell Bioscience, Inc.	215	
8.44.1	OrCell®	215	
8.45	Gamidia Cell Ltd.	216	
8.45.1	Gamidia's Technology	216	
8.46	GeneGrafts Ltd.	216	
8.46.1	GeneGrafts's Technology	217	
8.47	GenVec, Inc.	217	
8.47.1	GenVec's Product Programs	217	
8.47.1.1	TNFerade™	217	
8.47.1.2	Hearing and Balance	217	
8.48	Genzyme Corporation	217	
8.48.1	Genzyme's Business Performance	218	
8.48.2	Genzyme's Genetic Diseases Segment	219	
8.48.3	Genzyme's Hematology Oncology Segment	219	
8.48.4	Genzyme's Cardiometabolic and Renal Segment	220	
8.48.5	Genzyme's Biosurgery Segment	220	
8.48.6	Genzyme's Genetics and Diagnostics Segment	221	
8.48.7	Genzyme's Pipeline	221	
8.49	Geron Corporation	223	
8.49.1	Geron's Major Technology Platforms	223	
8.49.1.1	Role of Telomere in Cancer and Aging	223	
8.49.1.2	Human Embryonic Stem Cells: Source for the Manufacturing of Therapeutic Cells	223	
8.49.2	Commercial Opportunities for Geron's Major Technology Platforms	223	
8.49.2.1	Oncology	223	
8.49.3	Geron's Human Embryonic Stem Cell Therapies	224	
8.49.4	Geron's Patents and Proprietary Technology	224	
8.49.5	Geron's Business Performance	225	
8.49.6	Geron's Investment in Research and Development	226	
8.50	Harvest Technologies Corporation	226	
8.50.1	Harvest Technologies' Products	226	

8.50.1.1	SmartPreP®2 APC+™	226
8.50.1.2	SmartPreP®2 BMACTM	227
8.51	HemaStem Therapeutics, Inc.	227
8.51.1	Cord Blood Program	227
8.52	HepaLife Technologies, Inc.	228
8.52.1	Liver Disease	228
8.52.1.1	HepaMate™	228
8.53	Humacyte, Inc.	229
8.53.1	Humacyte's Products	229
8.54	Hydra Biosciences, Inc.	229
8.54.1	Hydra's Program	229
8.55	Intercytex Group plc	230
8.55.1	Vavelta®—Skin Repair and Rejuvenation	230
8.55.2	SHEF-1—Stem Cell Line	231
8.55.3	CX-SKN—Skin Graft Replacement for Burns and Acute Wounds	231
8.55.4	ICX-TRC—Hair Regeneration	232
8.55.5	Cyzact®—Chronic Wound Repair	232
8.56	Integra Lifesciences Holdings Corporation	232
8.56.1	Integra's Products	233
8.56.1.1	Integra's Orthopedic Product Portfolio	233
8.56.1.2	Dermal Regeneration and Engineered Wound Dressings	233
8.56.1.3	Nerve and Tendon	233
8.56.1.4	Bone Graft Substitutes for Extremity Reconstruction	233
8.56.1.5	Integra's OrthoBiologics	234
8.56.1.6	Duraplasty Products	234
8.56.2	Integra's Investment in Research and Development	234
8.56.3	Integra's Business Performance	235
8.57	International Stem Cell Corporation (ISCO)	235
8.57.1	Lifeline Cell Technology	235
8.57.2	Universal Stem Cell Bank	236
8.57.3	ISCO's Technology	236
8.58	Japan Tissue Engineering, Co., Ltd.	236
8.58.1	Autologous Cultured Epidermis	237
8.58.2	Autologous Cultured Cartilage	238
8.58.3	Autologous Cultured Corneal Epithelium	238
8.59	Karocell Tissue Engineering AB	239
8.59.1	Karocell's Autologous Cells	239
8.59.1.1	Keratinocytes	239
8.59.1.2	Melanocytes	239
8.59.1.3	Fibroblasts	239
8.59.1.4	Chondrocytes	240
8.59.1.5	Urothelial Cells	240
8.59.1.6	Karoskin™	240
8.59.1.7	Karoderm™	240
8.59.1.8	Cell Bank	240
8.59.2	Karocell's Research and Development	241
8.60	Kensey Nash Corporation	241
8.60.1	Biomaterials from Kensey	241
8.60.2	Kensey's Collagen Technology	241
8.60.3	Porous Tissue Matrix Technology	242
8.60.4	Kensey's Products	243
8.60.4.1	The Angio-Seal™ Vascular Closure Device	243
8.60.4.2	Vitoss® Scaffold Foam™	243
8.60.4.3	OsseoFit™ Porous Tissue Matrix™	243
8.60.4.4	Epi-Guide® Bioresorbable Barrier Matrix	244
8.61	Kiadis Pharma, BV	244

8.62	LifeCell	244
8.62.1	AlloDerm® Regenerative Tissue Matrix	244
8.62.2	Strattice™ Reconstructive Tissue Matrix	244
8.62.3	Cymetra® Micronized AlloDerm® Tissue	245
8.63	MaxCyte, Inc.	245
8.63.1	Advantages of MaxCyte Platform System	245
8.63.2	MaxCyte's Collaborations	245
8.63.3	MaxCyte's Application in Immunotherapy	246
8.63.4	MaxCyte's Application in Regenerative Medicine	246
8.63.5	MaxCyte's Viral Vectors and Vaccines	246
8.63.6	MaxCyte® XTS™ Scalable Transfection System	247
8.64	Mesoblast Ltd.	247
8.64.1	Mesoblast's Intervertebral Spinal Fusion	247
8.64.2	Lumbar Fusion	247
8.64.3	Cervical Fusion	248
8.64.4	Mesoblast's Intervertebral Disc Repair and Regeneration	248
8.64.5	Mesoblast's Product for Knee Osteoarthritis	248
8.64.6	Mesoblast's Investment in Angioblast Systems, Inc.	248
8.64.7	Angioblast's Product Candidate for Congestive Heart Failure	248
8.64.8	Angioblast's Product Candidate for Bone Marrow Transplantation	248
8.65	NanoCor Therapeutics, Inc.	249
8.65.1	NanoCor's Products	249
8.66	NeuralStem, Inc.	249
8.66.1	NeuralStem's Technology	249
8.66.2	NeuralStem's Research and Programs	250
8.66.3	NeuralStem's Intellectual Property	250
8.67	NeuroNova AB	252
8.67.1	NeroNova's Neurogenesis Qualifier—Technology	252
8.67.2	The sNN0029	252
8.67.3	The sNN0031	253
8.67.4	NeuroNova's Investors	253
8.68	Olympus Terumo Biomaterials Corporation	253
8.68.1	OSferion 60	254
8.68.2	Terudermis	254
8.68.3	Teruplug	254
8.68.4	Osferion 255	255
8.68.5	Bonaceram P	255
8.69	Opexa Therapeutics, Inc.	255
8.69.1	Opexa's T-Cell Platform	255
8.69.2	Opexa's Stem Cell Platform	256
8.70	Organogenesis, Inc.	256
8.70.1	Products from Organogenesis	256
8.70.1.1	Apligraf®	256
8.70.1.2	VCT01™	257
8.70.1.3	CelTx™ for Oral Soft Tissue Regeneration	257
8.70.1.4	FortaGen®	257
8.70.1.5	FortaPerm®	257
8.70.1.6	BioSTAR®	257
8.71	Orthovita, Inc.	258
8.71.1	Orthovita's Products	258
8.71.1.1	Vitoss	259
8.71.1.2	Vitoss and Bone Defect Grafting	259
8.71.1.3	Vitoss in Spinal Fusion and Grafting	259
8.71.1.4	Vitoss and Trauma	259
8.71.1.5	Vitomatrix™ and Dental, Periodontal, Oral and Craniomaxillofacial Defects	259
8.71.1.6	Cortoss Bone Augmentation Material	260

8.71.1.7	Cortoss and Vertebral Augmentation of Vertical Compression Fractures (VCFs)	260
8.71.1.8	Cortoss and Screw Augmentation	260
8.71.1.9	Orthovita's Aliquot Delivery System	260
8.71.2	Orthovita's Biosurgery Products	260
8.71.3	Partnership with Kensey for Vitoss Foam	261
8.71.4	Partnership with Angiotech for Vitagel and CellPaker	261
8.71.5	Partnership with Medafor for Vitasure	261
8.71.6	Orthovita's Business Performance	261
8.72	Osiris Therapeutics, Inc.	262
8.72.1	Osiris' Partnerships	262
8.72.2	Osiris' Technologies	263
8.72.3	Prochymal®	263
8.72.4	Chondrogen®	263
8.73	Osteotech, Inc.	264
8.73.1	Osteotech's Products	264
8.74	Pervasis Therapeutics, Inc.	265
8.74.1	Pervasis' Clinical Focus	265
8.74.2	Power of Endothelium	265
8.74.3	Therapeutic Applications of Pervasis' Products	265
8.74.3.1	Arteriovenous (AV) Access for Hemodialysis	265
8.74.3.2	Peripheral Arterial Disease	266
8.75	Pleuron	266
8.75.1	Pleuron's Technology	266
8.76	Pluristem Therapeutics, Inc.	267
8.76.1	Pluristem's PluriX™ 3D Bioreactor	267
8.76.2	Pluristem's PLacental eXpanded (PLX) Cells	267
8.76.3	PLX-PAD for Peripheral Artery Disease	267
8.76.4	PLX-IBD for Inflammatory Bowel Disease	267
8.76.5	PLX-MS for Multiple Sclerosis	267
8.76.6	PLX-STROKE for Ischemic Stroke	268
8.77	RegeneRx	268
8.78	ReNeuron Group plc	268
8.78.1	ReNeuron's Platform Technologies	268
8.78.2	ReNeuron's Cell Therapy Programs	270
8.78.3	ReNeuron's ReN001 for Stroke	270
8.78.4	ReNeuron's ReNcell® Products	271
8.79	Revivicor, Inc.	271
8.79.1	Revivicor's Xenografting Technology	271
8.79.2	Revivicor's Islet Transplantation Technology	271
8.79.3	Revivicor's Infectious Disease Platform Technologies	272
8.80	Saneron CCEL Therapeutics, Inc.	272
8.80.1	Saneron's U-Cord-Cell™ Program	272
8.80.2	Saneron's Sert-Cell™ Program	272
8.81	Sangamo BioSciences, Inc.	272
8.81.1	Sangamo's ZFP Therapeutic Product Development Programs	273
8.81.2	ZFP Therapeutic Pre-Clinical Stage Programs	273
8.81.2.1	Neuropathic Pain (Cancer Pain)	273
8.81.2.2	Nerve Regeneration—Spinal Cord Injury (SCI) and Traumatic Brain Injury (TBI)	273
8.81.2.3	Parkinson's Disease (PD)	274
8.81.2.4	Stroke	274
8.81.2.5	ZFP Therapeutic Research Programs	274
8.81.3	Funding from Research Foundations	274
8.81.3.1	The Juvenile Diabetes Research Foundation International	274
8.81.3.2	The Michael J. Fox Foundation	274
8.81.3.3	The Bill and Melinda Gates Foundation	274
8.81.4	Sangamo's Research and Development Expenses	274

8.81.5	Sangamo's Business Performance	275
8.82	StemCells, Inc.	276
8.82.1	StemCell's Cellular Medicine Programs	276
8.82.2	StemCells' Enabling Technologies Program	277
8.82.3	StemCells' Patents, Proprietary Rights and Licenses	278
8.83	Stem Cell Authority Ltd.	279
8.83.1	The "Miracle" Mesenchymal Stem Cell—Mirachymal Stem Cells	279
8.84	Stem Cell Innovations (SCI)	279
8.84.1	SCI's Research and Development	279
8.84.2	SCI's Services	279
8.84.3	PluriCells™ and Derivatives	280
8.84.4	ACTIVTox®	280
8.84.5	PredictivTox®	280
8.84.6	Endogenous Protein Production	280
8.85	Stem Cell Sciences KK	280
8.85.1	SCS KK's Product/Service	281
8.85.1.1	CultiCell Medium for Embryonic Stem Cells	281
8.85.1.2	Contract/Sponsored Research on ES-derived Functional Cells	281
8.86	SyntheMed, Inc.	281
8.86.1	Repel-CV® Adhesion Barrier	282
8.86.2	Resolve™ Adhesion Barrier Instillate	282
8.86.3	Repel™ Adhesion Barrier	282
8.86.4	SpineShield™ Adhesion Barrier Film	282
8.86.5	Relieve™ Adhesion Barrier Gel	282
8.86.6	SinusShield™ Adhesion Prevention Film	282
8.87	t2cure GmbH	282
8.87.1	BMCs in Regenerative Therapies	283
8.87.2	t2cure's Product Development Pipeline	283
8.88	Tengion	283
8.88.1	Tengion's Pipeline Overview	284
8.89	TiGenix	284
8.89.1	ChondroCelect®	284
8.89.2	Chondromimetic	285
8.89.3	TGX002285	
8.89.4	TGX003285	
8.90	Thermogenesis Corp.	285
8.90.1	Products from Thermogenesis	285
8.90.1.1	AutoXpress™ Platform or AXP®	285
8.90.1.2	MarrowXpress™	285
8.90.1.3	BioArchive® System	285
8.90.1.4	Res-Q™	286
8.90.1.5	Thermoline™	286
8.90.1.6	CryoSeal® Fibrin Sealant (CryoSeal) System	286
8.90.2	Thermogenesis' Business Performance	286

INDEX OF FIGURES

Figure 2.1: Geographic Distribution of 73 TERM Firms in the Five Focus Countries, 2009	29
Figure 2.2: Geographic Distribution of the 15 TERM Firms in Germany, 2009	30
Figure 2.3: Geographic Distribution of the Five TERM Companies in the U.K., 2009	31
Figure 2.4: The Potential Uses of Embryonic Stem Cells	32
Figure 2.5: Cell Culture Products by Market Segment	35
Figure 2.6: Estimated Global Market for Cell and Tissue Analysis Products, 2008-2014	35
Figure 2.7: Growth in Size of Cell Therapy Industry, 2000, 2002, 2003, 2008	41
Figure 2.8: Percent Break-Up of Cell Therapy Companies by Product Type, 2008	42

Figure 2.9: Location of Primary Tissue Engineering Companies by Geography, 2008-2009	43
Figure 2.10: Breakdown of Primary Cell Therapy Products on Market by Geography, 2008-2009	45
Figure 2.11: The Geographical Distribution of Clinical Trials, 2008-2009	49
Figure 2.12: Implantation of a Hydrogel at the Site of an Injured Tissue	59
Figure 2.13: Implantation of CS-PEG Hydrogel	60
Figure 2.14: Implantation of CMP-PEG Scaffold	60
Figure 4.1: Global Market for Regenerative Medicine Products, 2008-2013	82
Figure 4.2: Estimated Market for Regenerative Cell Therapy Products for Orthopedics, 2008-2012	83
Figure 4.3: Estimated U.S. Market for Regenerative Medicine Products, 2009-2014	83
Figure 4.4: Estimated U.S. Market for Bone Grafting/Bone Replacement, 2009-2014	84
Figure 4.5: Estimated U.S. Market for Bone Growth Stimulating Substances, 2009-2014	84
Figure 4.6: Estimated U.S. Market for Regenerative Products for Cartilage Repair, 2009-2014	85
Figure 4.7: Estimated Market for Stem Cells, 2008-2012	87
Figure 4.8: Estimated Market for Cell Therapy Products in the U.S., 2009-2018	88
Figure 4.9: Estimated Global Market for Cord Blood Stem Cells, 2010-2015	89
Figure 4.10: Worldwide Growth of Public Cord Blood Banks, 2005-2009	89
Figure 4.11: Worldwide Growth of Private Cord Blood Banks, 2005-2009	90
Figure 5.1: Cell-Based Business Models	92
Figure 5.2: Current Autologous Business Models	94
Figure 5.3: Current Allogeneic Business Models	95
Figure 7.1: CIRM's Grant Awards by Category, 2009	112
Figure 7.2: CIRM's funding by Disease Application, 2009	113
Figure 7.3: CIRM's Funding by Disease Category	114
Figure 7.4: Estimated Increase in Worldwide Funding for RM Research, 2008-2018	120
Figure 8.1: Aastrom's Investment in Research and Development, 2007-2009	124
Figure 8.2: Aastrom's Business Performance, 2005-2009	125
Figure 8.3: ACT's Business Performance, 2008 and 2009	128
Figure 8.4: ACT's Investment in Research and Development, 2008 and 2009	128
Figure 8.5: Aranesp® (Darbepoetin Alfa)'s Sales in the U.S. and International Market, 2007-2009	139
Figure 8.6: U.S. Market for Epogen®, 2007-2009	140
Figure 8.7: Global Market for Neulasta®, 2007-2009	140
Figure 8.8: Global Market for Enbrel® (Etanercept), 2007-2009	141
Figure 8.9: Global Market for Sensipar® (Cinacalcet), 2007-2009	142
Figure 8.10: Global Market for Vectibix® (Panitumumab), 2007-2009	142
Figure 8.11: Global Market for Nplate® (Romiplostim), 2007-2009	143
Figure 8.12: Amgen's Three Large Wholesale Customers, 2007-2009	144
Figure 8.13: Amgen's Overall U.S. and International Market, 2007-2008	144
Figure 8.14: Athersys' Investment and Development, 2007-2009	159
Figure 8.15: Athersys' Business Performance, 2005-2009	159
Figure 8.16: Current Capitalization of Cardio3's Investors, 2009	175
Figure 8.17: Celgene's Business Performance, 2005-2009	186
Figure 8.18: Curis' Business Performance, 2005-2009	203
Figure 8.19: Genzyme's Business Performance, 2005-2009	218
Figure 8.20: Genzyme's Percent of Revenue by Business Group, 2009	218
Figure 8.21: Geron's Business Performance, 2005-2009	225
Figure 8.22: Geron's Investment in Research and Development, 2005-2009	226
Figure 8.23: Integra's Investment in Research and Development, 2007-2009	234
Figure 8.24: Integra's Business Performance, 2005-2009	235
Figure 8.25: NeuroNova's Share Holders as of June, 2009	253
Figure 8.26: Orthovita's Business Performance, 2005-2009	262
Figure 8.27: Sangamo's Investment in Research and Development, 2007-2009	275
Figure 8.28: Sangamo's Business Performance, 2005-2009	275

INDEX OF TABLES

Table 2.1: Number of TERM Companies Identified in the Five Focus Countries, 2009	25
Table 2.2: Number of TERM Companies Developing Stem Cells Seeded to Scaffolds, 2009	25
Table 2.3: Number of Firms with Focus on Skin, Cartilage, Bone and Urological Applications, 2009	26
Table 2.4: Number of Firms Focusing on Cardiovascular Applications, 2009	27
Table 2.5: Number of Firms with a Focus on Neurological Applications, 2009	27
Table 2.6: Number of Firms Focused on Pancreas, Liver and Kidney Applications, 2009	28
Table 2.7: Number of Companies Focused on Autologous and Allogeneic Products, 2009	29
Table 2.8: Geographic Distribution of U.S. TERM Firms, 2009	30
Table 2.9: Geographic Location of 11 Out of 13 TERM Firms in Japan, 2009	31
Table 2.10: Geographic Distribution of the Three TERM Firms in Sweden, 2009	31
Table 2.11: Number of Patients Treated with Cell Therapeutics, 1988-2010	34
Table 2.12: Some Selected Suppliers of In Vitro Test Kits and Their Products	36
Table 2.13: Suppliers of Cells and Tissues	37
Table 2.14: Selected Suppliers of Media and Reagents	38
Table 2.15: Selected Providers of Equipments in Stem Cell Research	38
Table 2.16: Selected Providers of Computer Software for Stem Cell Research	40
Table 2.17: Geographical Distribution of Stem Cell-Related Tissue Engineering Companies, 2008	42
Table 2.18: Breakdown of Cell Therapy Firms by Country, 2008-2009	44
Table 2.19: Cell Therapy Products on the Market by Type and Application Area, 2008-2009	46
Table 2.20: Data on Sales and Application for Skin and Cartilage Products, 2006-2008	47
Table 2.21: Reagent Sales by Selected Stem Cell Companies, 2008	47
Table 2.22: Sales of Secondary Products, 2007	48
Table 2.23: Disease Focus of Clinical Trials, 2008-2009	50
Table 2.24: Stem Cell Products in Phase II/III Trials, 2008-2009	51
Table 2.25: Licensing Activities in Pharmaceutical and Cell Therapy Industries	56
Table 2.26: Investment Activity in Cell Therapy Sector	56
Table 2.27: Novel Partnership by Large Pharmaceuticals with Universities	57
Table 2.28: Cell Therapy Companies with Greater than Ten Million by Market Cap, 2008	58
Table 3.1: Regenerative Medicine Product Development Status, 2008	64
Table 3.2: Top Ten Regenerative Medicine Products, 2008	68
Table 3.3: Wound Healing Products	75
Table 4.1: Worldwide Estimates of Key Industry Parameters, 2007	86
Table 4.2: Potential U.S. Populations for Cell-Based Therapies	87
Table 5.1: The Required Elements of a Manufacturing Facility	97
Table 5.2: Cell Therapy CMO Qualification Audit: Points to Investigate	98
Table 6.1: Diseases with Potential Applications for Regenerative Medicine	100
Table 7.1: Stem Cell Policies in North America	107
Table 7.2: Stem Cell Policies in South America	108
Table 7.3: Stem Cell Policies in Europe	109
Table 7.4: Stem Cell Policies in Asia/Oceania	110
Table 7.5: CIRM Funded Grants To-Date	111
Table 7.6: List of Upcoming Request for Applications (RFAs) Showing Commitments from Funding Partners	113
Table 7.7: Recipients of Funds from Connecticut Stem Cell Research Program, 2009	115
Table 7.8: Maryland Stem Cell Research Fund, 2008	117
Table 7.9: NJCST's Award of Grants for Stem Cell Research, 2008	117
Table 7.10: NYSTEM's IIRP Awards, 2008	118
Table 7.11: NIH Funding for Regenerative Medicine and Stem Cell Research, 2003-2009	122
Table 7.12: NIH Funding for Various Types of Stem Cell Research, 2004-2009	122
Table 8.1: Patents Owned by ACT	127
Table 8.2: Patents Owned by ACT's Subsidiary Mytogen, Inc.	127
Table 8.3: Patents Licensed to ACT by the University of Massachusetts	127
Table 8.4: Alseres' Product Pipeline, 2009	132
Table 8.5: Amgen's Pipeline of Products	137
Table 8.6: Amgen's Approved Products	138

Table 8.7: AnGes' Current Pipeline Status, 2010	149
Table 8.8: Angioblast's Product Development Overview	150
Table 8.9: Angion's Product Pipeline	151
Table 8.10: Angion's Product Pipeline	153
Table 8.11: Arteriocyte's Product Pipeline	155
Table 8.12: Developmental Status of Athersys' Key Programs, 2010	156
Table 8.13: Bioheart's Pipeline Product Candidates	162
Table 8.14: BioLine's Product Pipeline, 2010	164
Table 8.15: BioMimetic's Current Product Candidates and Target Indications	166
Table 8.16: BioMimetic's Clinical Studies	166
Table 8.17: BioMimetic's Investment in Research and Development, 2005-2009	167
Table 8.18: BrainStorm's Intellectual Property	173
Table 8.19: Cardio3's promising Product Pipeline	174
Table 8.20: Cellerix's Product Pipeline	185
Table 8.21: Celgene's Leading Product Candidates	188
Table 8.22: Private Cord Blood Banking vs. Public Donation	202
Table 8.23: Curis' Current Research and Development Programs and Their Status	203
Table 8.24: Curis' Revenues from Research and Development, 2008 and 2009	204
Table 8.25: Regulatory Status of Celution [®] System	205
Table 8.26: Regulatory Status of PureGraft [™] and CelBrush [™]	205
Table 8.27: Devolgen's Pipeline Overview	207
Table 8.28: Epistem's Emerging Pipeline of Protein Therapeutics	213
Table 8.29: FivePrime's Product Pipeline	214
Table 8.30: FivePrime's Collaborations	215
Table 8.31: Gamidia's Pipeline Products	216
Table 8.32: Genzyme's Pipeline of Products	222
Table 8.33: Cancer Therapeutics and Diagnostic Products being Developed by Geron	224
Table 8.34: The hESC-derived Product Candidates Developed by Geron and its Collaborators	224
Table 8.35: Geron's Patent Portfolio	225
Table 8.36: Hydra's Product Pipeline	230
Table 8.37: Intercytex' Product Pipeline	230
Table 8.38: Kiadis' Product Pipeline	244
Table 8.39: NeuralStem's Issued and Pending Patents	251
Table 8.40: NeuroNova's Product Pipeline	252
Table 8.41: Orthovita's Existing Orthobiologic and Biosurgery Products	258
Table 8.42: Orthovita's Biosurgery Products	261
Table 8.43: Osiris' Therapeutic Product Pipeline	264
Table 8.44: Pervasis' Product Pipeline	266
Table 8.45: RegeneRx's Product Development Pipeline	268
Table 8.46: Summary of Sangamo's Current Clinical Programs	273
Table 8.47: Current Status of StemCells' Therapeutic Product Development Programs	276
Table 8.48: StemCells' Cell Culture Products	277
Table 8.49: StemCells' Patents Covering Stem and Progenitor Cells and Research Tools	278
Table 8.50: t2cure's Product Development Pipeline	283
Table 8.51: Tengion's Product Candidates Pipeline	284
Table 8.52: Thermogenesis' Business Performance by Geographic Area, 2007-2009	286

1. Overview

1.1 Statement of Report

Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms—like the starfish—man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine.

As such, the purpose of this report is to describe the emerging field of regenerative medicine. The areas covered in this study include: available and emerging technologies in the field, the U.S. and global market size for regenerative medicine products, and the profiles of companies that are focusing on regenerative medicine sector. The main objectives of this analysis are:

- Estimate the current and future U.S. and global markets for regenerative medicine.
- Assess market opportunities and the potential market pertaining to the disease indications.
- Discuss product development challenges in relation to regulatory constraints, legislative constraints and technical challenges.
- Analyze the need for regenerative medicine for the different disease indications.
- Understand the impact of current products and the future of regenerative medicine industry.
- Provide insight into the regenerative medicine products in the pipeline and the companies that strive to bring these products to the market in the immediate future.
- Evaluation global activity in regenerative medicine with specific contributions from the top-ranking five countries: U.S., Japan, Germany, U.K. and Sweden.
- Analyze the segments in regenerative medicine such as scaffolds, cells and tissues and biomolecules.
- Gain insight into the current applications of regenerative medicine in bone, heart, neurons, pancreas, eye and tooth.
- Explore drug discovery efforts in relation to regenerative medicine.
- Analyze the usual hurdles regenerative medicines are encountering to reach the market and the right path to the market for these products.
- Review the current licensing, investing and partnering activities in regenerative medicine sector.
- Assess business models and requirements for a successful regenerative medicine industry.
- Examine funding scenario for the regenerative medicine sector.
- Identify the key players in the regenerative medicine industry and their contribution to this emerging therapy.

Key questions answered in this study are:

- What according to the U.S. National Institute of Health (NIH) are the products that come under the phrase “regenerative medicine”?
- What disease conditions offer the greatest potential for regenerative medicines?
- What is the current global market for regenerative medicine?
- How much of clinical development activities are taking place globally in regenerative medicine sector?
- How many companies are involved in the development of regenerative medicine products?
- How many patents have been issued for regenerative medicine products?
- How long would it take to develop tissues on demand?
- Which healthcare segments can make an easy entry into the regenerative medicine market?
- What regulatory and technical challenges are being confronted by the regenerative medicine industry?
- Which countries are in the forefront of developing regenerative medicine?

- What are the current promising developments in regenerative medicine sector?
- Which countries have made strong commitments to achieve supremacy in the race for these future-medicines?
- What is the latest position of the clinical studies and product pipe line in regenerative medicine sector?
- How long it will take for the regenerative medicine therapies to become the standard of care to replace all damaged tissues and organ systems in the body?
- How much of venture capital fund was invested into the regenerative medicine sector?
- What is the financial commitment made by governments other than the U.S., such as Japan, China, South Korea and Singapore?
- What is the potential population in the U.S. for cell therapies?
- Do the developing countries which comprise the largest populations offer scope for the regenerative medicine product?
- What are the probable top-ten applications of regenerative medicines in the developing countries?
- What are the top-ten regenerative medicine products available in the market place?
- What are the available wound healing regenerative medicine products in the market?
- What are the cartilage regeneration products available in the market?
- How many companies are involved in the development of skin, cartilage, bone, urological products?
- How many companies are focused on the development of regenerative cardiovascular products?
- How many companies are engaged in the development of regenerative neurological products?
- How many firms concentrate on pancreas, liver and kidney products?
- Which firms are involved in the development of ophthalmic products?
- Which companies are focused on the development of dental regenerative products?
- Which companies are focusing on the manufacture of growth factors?
- Which companies are involved in marketing drug screening products for toxicology tests?
- Which companies are associated with developing biomaterials in relation to regenerative medicine?
- Is there an easy market path to products of regenerative medicine?
- How many companies develop autologous and allogeneic cell therapy products?
- What are the different business models suitable for the different types of regenerative medicine products?
- What are the requirements for the commercial manufacturing of regenerative medicine products?
- What are the different funding sources in the U.S. for the development of regenerative medicine products?

This report contains:

- Current market opportunities for regenerative medicine products.
- Product development challenges confronted by the regenerative medicine industry.
- A brief discussion on the need for regenerative medicine and the advantages of cell therapy over the conventional pharmaceutical medicines.
- A brief note on the current state of regenerative medicine.
- The future direction of the emerging regenerative therapy treatments.
- The overall picture of pipeline products in regenerative medicine sector and the companies involved.
- A brief note on the projected time-line for regenerative medicine.
- A market projection for global regenerative medicine products.
- A short note on the potential number of U.S. patients requiring regenerative therapy as based on an estimate from the American Heart Association, the American Autoimmune Disease Association, American Burn Association, etc.
- A detailed discussion on the potential market for regeneration therapies in the thickly populated but economically weak developing countries.
- Listing and explaining the most popular regenerative medicine products in the market.
- Presentation of the global picture of the regenerative medicine industry with particular reference to the leading countries, such as U.S., Japan, Germany, U.K. and Sweden.
- Number of firms engaged in regenerative medicine (RM) products for skin, cartilage, bone and neurological applications in the above five leading countries.
- Number of RM firms focusing on cardiovascular applications in the five leading countries.

- Number of RM firms concentrating on neurological applications in the five leading countries.
- Number of RM firms specializing on pancreas, liver and kidney applications.
- Leading RM firms in ophthalmic applications.
- Key RM players in dental applications.
- Leading companies in the field of drug discovery using cells and tissues as tools.
- Leading firms focusing on biomaterials used in regenerative therapy.
- A detailed discussion on RM product's path to market.
- A detailed account on business models and requirements for a successful RM industry.
- A brief note on in-house and contract manufacturing options for an RM industry.
- A note on global funding for RM industry.
- A brief introduction to U.S. federal funding for RM in the past, present and future.
- Listing of all the diseases with potential applications for regenerative medicines.
- A brief discussion on international collaboration on RM research.
- In-depth profiles of 90 companies involved in research and development (R&D) of products in biomaterials, cell therapy products and tools related to RM.

1.2 Scope of this Report

This report provides a thorough overview of regenerative medicine (RM) sector together with analyses of the funding trends, intellectual property, market opportunities and emerging areas of applications, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures in this emerging field. The report enables the reader gain in-depth knowledge about the various ongoing research programs carried out in the U.S. universities and other research centers. Since regenerative medicine is an emerging field, only about five countries such as the U.S., Japan, Germany, U.K. and Sweden seem to play an important role, and this report gives the details such as the number of firms and the types of products manufactured in these five focus countries. The various business models in cell therapy have been described in detail so that the companies expanding their operations can have an insight into the best model suitable for their new ventures. The appendix part of this analysis carries an exhaustive list of consultants who are in this field for several years offering consultancy services for new entrants into this field. This study also covers the companies that are actively developing and marketing RM products. Other TriMark Publications reports related to different healthcare segments can be found at <http://www.trimarkpublications.com>.

1.3 Methodology

The author of this report is a retired college professor with three decades of experience in teaching biochemistry, biotechnology, pharmacology, environmental biology and horticulture. The detailed study of this report is based mainly on the publications of primary research on regenerative medicine, as well as information from venture capital firms. For the publicly held companies, the annual reports, 10-K filings and financial reports were examined. Information available from the proprietary databases at Biotechnology Associates and from the private data stores of TriMark Publications was also used in preparing this report. Important data sources include American Heart Association, American Autoimmune Related Disease Association, American Burn Association, *World Stem Cell Report 2008 and 2009*, Swedish Governmental Agency for Innovative System (VINNOVA) and research centers from the U.S. universities. The market data given in this report are based on available market data from press releases and company annual reports. Company profiles were gathered from the annual reports, conference proceedings and Internet searches. The information set forth in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information, any omission or the results obtained by the use of such information.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects and Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark's research in the past three years as part of this data collection. We also extract qualified data feeds from e-questionnaire responses and primary research responses for this compilation.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government affiliated trade releases, and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations. The report conclusions are verified through intensive interviewing of the top-ranking companies in the industry.

TriMark Publications Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners.

1.4 Executive Summary

This study discusses the current state and activities of an up-coming and fast-developing knowledge field of regenerative medicine (RM). RM has been made possible by tissue engineering and, therefore, much of the discussion in this study is about both tissue engineering and regenerative medicine (TERM). TERM focuses on medical treatments to repair tissues and organs using bioengineered materials, cellular technologies and some forms of implants. The report also aims to identify the future initiatives that would stimulate knowledge creation and innovation processes leading to new therapies and products beneficial to patients in a global perspective.

The science of tissue engineering includes the development of therapeutic solutions based on a combination of scaffolds based on biomaterials, cells and tissue and biomolecules. Although, the report mentions several countries in this sector, only five of these countries (U.S., Japan, Germany, U.K., and Sweden) are the focus-countries of this analysis. In these focus-countries, there are about 303 companies actively engaged in regenerative medicine and 77 of these companies are engaged in the development of organ-specific and tissue-engineered products. About 230 companies are pharmaceutical industries focusing on drug discovery and development by using stem cells. Some of them are developing drugs to be used in regenerative medicine. Some are engaged in the development of tools

required for used in TERM applications. There are also some companies focusing on biomaterials for RM applications.

Almost all categories of RM companies are found in the U.S., but the country's strength is more pronounced in neurology, pancreas, kidney and liver applications. Germany is strong in skin, cartilage, bone and urological applications. Only the U.S. and Germany have projects in cardiovascular applications in clinical trials. Japanese companies are sound in skin, cartilage, bone, cardiovascular and urological applications. Companies in U.K. are active in skin, cartilage, bone and urological applications. As the companies currently engaged in biocompatible materials may face severe competition, they too are likely to enter the RM field. Although a huge market has been predicted for RM products in future, for many companies, this is still wishful thinking than a reality. The specific challenges for RM firms to reach the market include: public and political acceptance, selection of type of cell source, types of business model, and benefits/drawbacks of a firm's specific geographic location.

Today, Europe has a common regulation aiming at advanced-therapy medicinal products that include products based on genes, cells and tissues and centralized marketing authorization procedure. Europe, thus, faces a much improved regulatory situation. There are, however, variations as to policies, volume of investments, profile areas and applied research in the five focused countries. The U.S. leads in scientific output in terms of publication volume. Asian countries such as China, South Korea and Taiwan also are displaying an interest in this emerging field.

Among the individual research organizations, Harvard University is outstanding in the field of stem cell research. Other than the U.S. organizations, the top universities in stem cell research are located in countries like Japan, Sweden, England, Switzerland, Germany, Singapore, Italy and Canada. In stem cell research relating to neuroscience, the top non-U.S. organization is the Japanese Kyoto University in third position and the Swedish Karolinska Institutet is the top European organization.

In biomaterials research fields, the U.S., Japanese, German and Singaporean research environments hold the most prominent positions. The Universities of Toronto, Kyoto, Singapore, Bern, Seoul, Michigan, Bologna and Texas hold top positions in the statistics depending on biomaterial field. Swedish researchers are strong in the field of osteointegration, and in this field, Gothenburg University seems to outperform most other organizations.

This study provides separate comprehensive analytics for the U.S., Japan, Germany, U.K. and Sweden. Annual data are provided for tissue engineering and regenerative medicine products for the years 2008 to 2013. The report profiles 90 companies including many important players globally such as Amgen, Inc., Arthersys, Inc., Bioheart, Inc., Biomet, BioMimetic Therapeutics, Inc., Cellartis AB, Cellerix, Celgene Corporation, Cytos Therapeutics, Inc., Gamida Cell Ltd., Genzyme Corporation, Geron Corporation, Organogenesis, Inc., Osiris Therapeutics, Inc., Reneuron Group plc, Stryker Corporation, etc. The aim of this study is to provide, an overview of the global commercial landscape in regenerative medicine, the strength of the participating companies, and the scope for the hopeful new entrants into the sector. The time is ripe for the pharmaceutical giants to enter the new field and contribute their might to the development of cell therapies for the betterment of human health.